A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

Lind MJ, Cantwell BM, Millward MJ, Robinson A, Proctor M, Simmons D, Carmichael J, Harris AL

British journal of cancer1 Apr 1992Cited by 18 (Europe PMC)

PMID1314071PMCIDPMC1977567DOI10.1038/bjc.1992.126PepBankPUB-01314071

Summary

Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin. There were two partial responses lasting 40 and 105 weeks respectively. In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively and 23 patients had progressive disease. No significant or unexpected toxicities occurred. This minimally toxic therapy halted disease progression for 6 months or more in 23% of patients, the majority of whom were heavily pretreated. There were five early deaths due to disease progression. The use of goserelin in patients with epithelial ovarian cancers resistant to or relapsing soon after first line platinum based chemotherapy needs to be further evaluated.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In advanced epithelial ovarian cancer, goserelin produced two partial responses lasting 40 and 105 weeks.
In plain wordsIn advanced ovarian cancer, two patients had partial responses to goserelin lasting 40 and 105 weeks.
Peptide
Goserelin
Outcome
Not applicablePartial responses
Study
n = 30
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Partial responses
2 patients
goserelin
Response duration
40 weeks
first response
Response duration
105 weeks
second response
Source sentences
Summary
There were two partial responses lasting 40 and 105 weeks respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin.
Show in the study text Report a problemFND-0131407101
02HumanNon-randomized trialEfficacy outcome
In advanced epithelial ovarian cancer, five patients had disease stabilisation with goserelin lasting 25, 35, 40, 66 and 70 weeks.
In plain wordsIn advanced ovarian cancer, five patients had stable disease with goserelin for 25, 35, 40, 66 and 70 weeks.
Peptide
Goserelin
Outcome
Not applicableDisease stabilisation
Study
n = 30
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Stable disease
5 patients
goserelin
Stabilisation duration
25 weeks
patient
Stabilisation duration
35 weeks
patient
Stabilisation duration
40 weeks
patient
Stabilisation duration
66 weeks
patient
Stabilisation duration
70 weeks
patient
Source sentences
Summary
In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively and 23 patients had progressive disease.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin.
Show in the study text Report a problemFND-0131407102
03HumanNon-randomized trialEfficacy outcome
In advanced epithelial ovarian cancer, 23 patients had progressive disease during goserelin treatment.
In plain wordsIn advanced ovarian cancer, 23 patients had disease progression during goserelin treatment.
Peptide
Goserelin
Outcome
Not applicableProgressive disease
Study
n = 30
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Progressive disease
23 patients
goserelin
Source sentences
Summary
In addition five patients had disease stabilisation lasting 25, 35, 40, 66 and 70 weeks respectively and 23 patients had progressive disease.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin.
Show in the study text Report a problemFND-0131407103
04HumanNon-randomized trialSafety outcome
In advanced epithelial ovarian cancer, no significant or unexpected toxicities occurred with goserelin.
In plain wordsIn advanced ovarian cancer, no significant or unexpected toxicities occurred with goserelin.
Peptide
Goserelin
Outcome
Not applicableSignificant or unexpected toxicities
Study
n = 30
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Source sentences
Summary
No significant or unexpected toxicities occurred.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin.
Show in the study text Report a problemFND-0131407104
05HumanNon-randomized trialEfficacy outcome
In advanced epithelial ovarian cancer, goserelin halted progression for 6 months or more in 23% of patients.
In plain wordsIn advanced ovarian cancer, goserelin halted progression for at least 6 months in 23% of patients.
Peptide
Goserelin
Outcome
Not applicableProgression halted for at least 6 months
Study
n = 30
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Progression halted
23%
6 months or more
Source sentences
Summary
This minimally toxic therapy halted disease progression for 6 months or more in 23% of patients, the majority of whom were heavily pretreated.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin.
Show in the study text Report a problemFND-0131407105
06HumanNon-randomized trialSafety outcome
In advanced epithelial ovarian cancer, five early deaths due to disease progression occurred during the goserelin trial.
In plain wordsIn advanced ovarian cancer, five early deaths from disease progression occurred during the goserelin trial.
Peptide
Goserelin
Outcome
Not applicableEarly deaths due to disease progression
Study
n = 30
Outcome group
Mortality · Cancer
Studied dose
Dose not stated
Measurements
Early deaths
5 patients
disease progression
Source sentences
Summary
There were five early deaths due to disease progression.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty patients with advanced epithelial ovarian cancer were treated with the luteinising hormone releasing agonist, goserelin.
Show in the study text Report a problemFND-0131407106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.